Issue link: http://osercommunicationsgroup.uberflip.com/i/365683
C h a i n D ru g s to re D a i l y M o n d a y, Au g u s t 2 5 , 2 0 1 4 2 4 CLINICAL EXPANSION DRIVES PHARMACY PROFITS In recent years, the practice of pharmacy has changed. Profit per script has been reduced with the expansion of generic drugs. PBMs have successfully prolifer- ated closed and limited networks which force retail pharmacies to accept lower margins in exchange for access to patient lives. All across the country, the economy has impacted patient's day to day deci- sions. With all these forces working against profit in retail pharmacy, why not seek solutions that have proven to gener- ate profit? MarkeTouch has developed its RxTouch service line to specifically increase revenue, efficiency and patient satisfaction, all which result in higher profitability for its clients. In fact, Outbound Notifications has, on average, reduced clients return-to-stock (RTS) rates by 40 percent, resulting in a $600,000+ increase in profitability for every million prescriptions filled. Additionally, by automating day-to-day patient communications with RxTouch, including medication changes and third- party conflicts, pharmacies have reduced their inbound call volume by an average of 35 percent and increased refills by eight percent. All of these metrics result in measurable dollars that flow to the bot- tom line. MarkeTouch has invested heavily in developing cutting-edge technology solutions, expanding its platform from patient communications to being a full service clinical provider. For example, its medica- tion synchronization service, Optimum MedSync, is a fully cus- tomizable robust engine that empowers pharmacists to have tar- geted clinical conversations with their patients while easing workflow burden on pharmacy staff. MarkeTouch's clini- cal staff brings industry leading expertise and a vast knowledge of industry best practices to effectively deploy clinical programs designed to meet client's goals and metrics. MarkeTouch has developed a clini- cal service suite that enables its clients to manage specialty patients. Specialty Pharmacy is a hot topic in health care right now. Many people realize that spe- cialty drugs are costly, and caring for the critically and chronically ill patients takes much more than just filling scripts. MarkeTouch's clinical service suite enables its clients to manage special- ty patients and document information required to ensure prompt and com- plete payment. RxTouch Pharmacist Connect is a fully hosted solution that streamlines operations within the pharmacy and gives patients options for their personal communication from the pharmacy. By utilizing the patients' preferred method of communication, greater adherence and persistency to the prescribed medication regimen can be achieved. This reduces overall healthcare costs and ultimately delivers better clinical outcomes for the patients. For more information, visit MarkeTouch Media at booth 307 or online at www.rxtouch.com. BANNER UTILIZES SOFTGEL DELIVERY TECHNOLOGIES OF THE FUTURE Banner Life Sciences™ ("Banner") is a global corporation dedicated to the research and development, in-licensing, out-licensing and commercialization of innovative formulation technologies, as well as the marketing of prescription, over-the-counter and nutritional propri- etary products. Banner is the products and technolo- gies division of DPx Holdings B.V.("DPx") DPx is a new privately held company owned by JLL Partners and Royal DSM and corporate parent of a group of business units comprised of Banner, Patheon and DSM Fine Chemicals. With global headquarters in Durham, N.C., DPx has a footprint of 24 locations across North America, Europe, Latin America and Australia with more than 8,000 employees. You benefit from the company's unique combination of entrepreneurial flexibility and extensive global resources to meet most any need across the entire product life cycle. As a respected leader in the softgel industry, Banner's global R&D scientists work in state-of-the-art laboratories in the U.S., as well as in Europe and Mexico, to develop OTC/Rx and nutri- tional supplement products combined with the softgel delivery technologies of the future. Banner focuses on the devel- opment of condition-specific supple- ments delivered with innovative, patent- pending technologies. Banner utilizes the same exacting criteria in the development, testing and manufacture of its dietary supplements as it does in its pharmaceutical products. FDA standards are applied to the analyti- cal processes, and manufacturing is con- ducted under the requirements of current good manufacturing practices. Banner's suppliers of raw materials must meet stringent quality-testing guidelines for purity and potency. Multiple critical and delicate process parameters are neces- sary in the production of a robust softgel cap- sule, and Banner blends the art and sci- ence of softgel technology to ensure a quality-consistent manufacturing process. In addition to the considerable expe- rience and fundamental scientific knowl- edge that is required for the production of quality dietary supplements, Banner applies innovation to encapsulation. Because Banner is a drug delivery and development company, it has created unique technology platforms to enhance the inherent benefits of softgels – the dosage form preferred by consumers, according to Banner Fish Oil Focus Groups, May 2012. The softgel technolo- gies include: EnteriCare ® Anti-Reflux Softgels, Versatrol™ Controlled Release Softgels, Chewels ® Chewable Gels, and EcoCaps™ Non-Animal Softgels, Softlet ® Gelcaps, Solvatrol™ Enhancing Solubility, and LiquiSoft™ Chewable Liquid Softgels. Banner's EnteriCare Anti-Reflux delivery system integrates enteric properties direct- ly into the gelatin shell. Conventional enteric methods uti- lize a spray coating that can crack or chip, potentially compromising the integrity of the capsules. Using EnteriCare technology, Banner has developed a line of EnteriCare Anti- Reflux Fish Oil products which provide an all-natural GRAS pectin-based enteric delivery for reduced reflux and fishy aftertaste. In addition, these products have passed the USP test for enteric soft- gel delivery (March 2011). Market research shows that consumers prefer the all-natural, clear, golden EnteriCare soft- gels to conventional enteric-coated fish oil softgels. Banner's full line of EnteriCare Anti-Reflux Fish Oil products includes multiple strengths as well as fish oil in combination with other heart- healthy vitamins and supplements. For more information, visit booth 150, call 336-812-8700 or go to www .bannerls.com.